Symptoms [SAPS), Scale for Assessment of Negative
Symptoms [SANS), Hamilton Rating Scale for Depression, and Simpson-Angus Extrapyramidal) at baseline and weekly during this three-week period. Negative symptoms, as measured by the SANS, worsened significantly during the three-week drug wash. Positive symptoms showed a less consistent change with symptoms of disorganization worsening and with psychotic symptoms remaining the same. The changes in negative symptoms during the drug-free period were correlated with the changes in psychosis and disorganization, but not with changes in depression or extrapyramidal side effects. We were not able to substantiate if the worsening in negative symptoms was a direct result of the worsening of positive symptoms or if they were changing simultaneously, but independent of each other. lNeuropsychopharmacology 11:11-20, 1994J associated with schizophrenia, they have been divided into two major categories: positive symptoms and nega tive symptoms. Using this archetype, positive symp toms as a group represent a distortion or excess of nor mal function, and include hallucinations (disturbance of perception), delusions (disturbance of cognition), for mal thought disorder (disturbance of language), and bizarre behavior (disturbance in behavioral control). On the other hand, negative symptoms represent a loss or diminution of normal function and are comprised of aff ective flattening (restricted experience of emotion and restricted expressiveness), avolition (loss of volition and drive), anhedonia (loss of interest), and alogia (loss of fluency of thought) (Jackson 1875) .
Although the importance of negative symptoms were recognized by both Kraepelin (1919) and Bleuler 0893-133X/94/$7.00 (1950) as the most important symptoms of schizophre nia, they were virtually ignored in psychiatric nosol ogy during the 1970s and mid-1980s because of the rel ative weight given to positive symptoms, especially frrst-rank symptoms. The renewed interest in negative symptoms within the past decade is partly due to the work of Strauss and Carpender (1974) , Crow (1980) , and Andreasen (1982) , who emphasized the ubiquitous na ture of these symptoms, and the excess morbidity as sociated with them. With this increased interest in nega tive symptoms, research investigating neurobiological correlates, pathophysiology, and the treatment of nega tive symptoms has blossomed.
Prior to the 1980s, the pharmacological treatment of schizophrenia focused almost exclusively on the reduction of florid symptoms such as hallucinations, delusions, bizarre behavior, and formal thought disor der with little attention to negative symptoms. Research examining the efficacy of antipsychotics in treating negative symptoms was stimulated by Crow's (1980) intriguing proposal that the negative symptoms of schizophrenia are generally not responsive to phar macological treatment. This inference was based pri marily on a study by Johnstone, et al. (1978) , who demonstrated that cis-flupenthixol, an effective dopa mine, 02, receptor antagonist in the thioxanthine class, was no more effective in treating negative symptoms than its dopaminergically inactive isomer. At least three other groups have reported fmdings suggesting that negative symptoms are not effectively treated by typi cal antipsychotics (Clark et al. 1963; Serafetinides et al. 1972; Angrist et al. 1980 ). In contrast, there have been reports revealing that negative symptoms can be par tially improved in a subgroup of schizophrenics treated with conventional antipsychotics (Goldberg 1965; Breier et al. 1987; Angst et al. 1989; Coryell et al. 1990; Tan don et al. 1990; Meltzer et al. 1991) , and a number of studies indicating that the atypical antipsychotics like clozapine (Kane et al. 1988; Miller et al. 1994 ) and risperi done (Castelao et al. 1989; Bressa et al. 1991; Chouinard et al. 1993 ) may be even more effective in ameliorating negative symptoms. There is now a general consensus that antipsychotics reduce negative symptoms during the successful treatment of positive symptoms, but that they improve at a slower rate and not as thoroughly as positive symptoms improve (Meltzer et al. 1986) . What remains controversial is if negative symptoms that represent a primary psychopathological trait manifesta tion of schizophrenia are effectively treated by anti psychotic medications.
One of the most difficult problems in the study of negative symptoms in schizophrenia involves the rec ognition that objectively assessable negative symptoms may occur as a consequence of a variety of factors. They can be "primary," related to the underlying pathophys iology of schizophrenia, or they can be "secondary" to NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 several distinct pathogeniC mechanisms. The most com monly implicated mechanisms responsible for "second ary" negative symptoms include: (1) positive symptoms (e.g., social avoidance secondary to paranoia); (2) neu roleptic side effects (e.g., akinesia); (3) depression (which is common in schizophrenia, particularly dur ing the residual phase) (Sirus 1991); and (4) environ mental understimulation resulting from chronic institu tionalization. Attempting to assess changes in negative symptoms in patients whose pharmacolOgical treatment is being manipulated, and in particular to determine the effect of a specifIc pharmacological treatment on negative symptoms, is therefore very complex. Phar macological treatment may have diff erent effects on "primary" and/or "secondary" factors that are sub sequently reflected as changes in ratings of negative symptoms.
Studies that have reported an improvement in negative symptoms with antipsychotic treatment, generally have discovered that the change in negative symptoms occurred in the context of an improvement in positive symptoms (Goldberg 1985; Breier et al. 1987; Angst et al. 1989; Coryell et al. 1990; Tandon et al. 1990; Meltzer et al. 1991) . However, the investigators were unable to ascertain if this was a direct cause-and-effect relationship or an independent, simultaneous improve ment. Others have proposed that reduction in extrapy ramidal symptoms (EPS) and/or depression can also mimic improvement in negative symptoms and need to be accounted for (Carpenter et al. 1985a ). Although several of the studies analyzed the correlation between the changes in negative symptoms and the changes in positive symptoms (Breier et al. 1987; Tandon et al. 1990) , none examined the degree to which improve ment in negative symptoms was correlated with a reduction in depression or EPS.
Another approach towards investigating the effect that antipsychotics have on negative symptoms has been to monitor negative symptoms during antipsy chotic withdrawal (Naber et al. 1985; Breier et al. 1987) . These studies assume that the change in negative symp toms associated with antipsychotic withdrawal is op posite the effect on negative symptoms that occurs with antipsychotic treatment (i.e., if negative symptoms worsen following antipsychotic discontinuation, it is assumed that the antipsychotics had previously been effective in reducing negative symptoms). Naber and colleagues (1985) studied a group of 36 chronic, schizo phrenic patients who were rated clinically while receiv ing neuroleptic therapy and who were rated during 12 days of antipsychotic withdrawal. They reported that discontinuation of long-term neuroleptic treatment was associated with improvement in the BPRS anergic scores and the deterioration of BPRS thought disorder scores. In contrast, Breier and associates (1987) observed that there was an exacerbation in both negative and positive symptoms in a group of 19 young schizophren ics who were withdrawn from antipsychotics for four weeks. There was no correlation between the change in the BPRS negative symptom rating and the change in BPRS positive symptoms cluster ratings. Neither study used standardized assessment instruments specifIcally design to rate negative symptoms nor thor oughly investigated if interactions of changes in other symptoms (i.e., depression and/or EPS) were mimick ing a change in negative symptoms.
In a further attempt to evaluate the effect of anti psychotics on negative symptoms, we examined the changes in negative and positive symptoms, ratings of depression, and EPS in a group of 59 chronic schizo phrenics who were withdrawn from antipsychotic med ications for 3 weeks. We also explored the interrelation ship between the changes in the various symptoms to determine if the change in negative symptoms was sec ondary to changes in other symptoms. We hypothe sized that negative symptoms would increase as posi tive and depressive symptoms increased, and that the changes would be correlated. We further hypothesized that this worsening of negative symptoms would oc cur even though there would be a simultaneous reduc tion in EPS.
METHODS

Subjects
We evaluated a sample of fIfty-nine consecutive patients who gave written, informed consent, before they underwent a three-week antipsychotic medication washout as part of a protocol for the University of Iowa Mental Health Clinical Research Center. All patients met DSM ID-R (1987) criteria for schizophrenia and had been receiving an oral antipsychotic prior to the study. Individuals who had received depot antipsychotic within the previous six months or had co-existing med ical problems were excluded. There were 18 female and 41 male subjects in the sample with a mean age of 32.6 ± 9.8 years. They had been ill for 13.2 ± 4.5 years and had 4.6 ± 4.2 previous hospitalizations. Forty-three of the 59 subjects were part of the data base used to dem onstrate the usefulness of various statistical methods for analyzing repeated measures of data ).
Procedures
After an initial baseline assessment period of 3 to 5 days, patients' antipsychotic medications were tapered and discontinued over a 2 to 3 day period. They then re mained off medication for 3 weeks. The wash was ter minated if a patient requested that it be discontinued or if the patient became threatening or physically agAntipsychotic Effects on Negative Symptoms 13 gressive. Just prior to the drug discontinuation, 23 pa tients had been taking haloperidol (mean dose 26.9 mg/day; with a range of 5 to 85 mg/day), 18 had been taking thiothixene (mean dose 37.4 mg/day; with a range of 5 to 80 mg/day), 7 had been taking fluphena zine (mean dose 24.6 mg/day; with a range of 2 to 60 mg/day), 3 had been taking trifluoperazine (mean dose 23.0 mg/day; with a range of 4 to 50 mg/day), 2 had been taking chlorpromazine (mean dose 200.0 mgt day), 2 had been taking molindone (mean dose 50.0 mg/day; with a range of 25 to 75 mgt day), 1 had been taking lox apine (dose 100 mg/day), and 3 had been taking com binations of two diff erent antipsychotics (thioridazine and fluphenazine, trifluoperazine and chlorpromazine, and trifluoperazine and thioridazine).
Clinical Assessment
Patients were assessed clinically by means of the CASH (Andreasen 1987; Andreasen et al. 1992 ). This struc tured interview, developed at our center to assess pa tients with major psychoses, provides comprehensive details of sociodemographic data including educational history, work history, and social history. It also con tains several standard scales used to rigorously assess psychopathology, such as the Scale for Assessment of Positive Symptoms (SAPS) (Andreasen 1984) , Scale for Assessment of Negative Symptoms (SANS) (An dreasen 1982; Andreasen 1983), the Global Assessment Scale (GAS) (Endicott et al. 1976) , the Mini-Mental State Examination (MMSE) (Folstein et al. 1975) , and the Premorbid Asocial Adjustment Scale (Gittelman-Klein and Klein 1969). Assessments were determined, based on direct observation of the patient, the self-report dur ing the interview, the interviews with informants, the reports by nursing personnel, and the reports from referring physicians.
Research nurses completed ratings of psycho pathology and side effects upon inclusion in the study, and then weekly during the drug washout. Assessment (Andreasen et al. 1992) .
Ratings from the SAPS and SANS were divided into three symptom dimensions (negative symptom dimension, psychoticism dimension, and disorganiza tion dimension) described in previous factor-analytic studies (Bilder et al. 1985 ; Andreasen and Grove 1986; Negative symptom dimension 11.1 ± 3.9 11.3 ± 3.9 Disorganization dimension 3.2 ± 2.9 4.1 ± 3.1 Psychoticism dimension 5.5 ± 2.8 5.0 ± 2.7 Simpson Angus 2.7 ± 3.3 2.4 ± 3.7 HAM-D (mood)
1.7 ± 2.3 1.9 ± 2.4 AlMS 2.3 ± 3.3 2.8 ± 4.3 GAS 34.6 ± 8.5 30.8 ± 9.3 df = 1. Liddle 1987; Gur et al. 1991; Arndt et al. 1991; Miller et al. 1993) . The Psychoticism Dimension included the global ratings of hallucinations and delusions; the Dis organization Dimension was comprised of the global ratings of bizarre behavior, formal thought disorder and inappropriate affect, and Negative Symptom Dimen sion was comprised of the global ratings of affective flattening, alogia, avolition-apathy, and anhedonia asociality from the SANS (Arndt et al. 1991; .
Using a principal component analysis, Goldman et al. (1992) reported that there was a large overlap be tween many items on the HAM-D and SANS negative symptoms in schizophrenia and suggested that the HAM-D items of depressed mood, guilt, and suicidal ideation represent "core" depressive symptoms in schizophrenic patients. Based on these flndings, we used a sum of the HAM-D items of depressed mood, guilt, and suicidal ideation as an independent measure of depression, which is referred to as HAM-D (mood).
Data Analysis
The mean baseline and the weekly ratings of psy chopathology and side effects were compared to deter mine if there was a change over the three-week drug wash. Prior to analyzing the seven dependent variables with a standard repeated measures ANOVA (Le., ran domized block design), checks for the assumed condi tion of sphericity (Ekstrom et al. 1990) were made with the likelihood ratio test (Mauchly 1940; Rogan et al. 1984) . In six of the seven scales, the sphericity condi tion was untenable (p < 0.05). Because only one of the seven seemed to satisfy the condition, we used the mul tivariate analog of repeated measures, ANOVA, to ob tain tests for overall mean diff erences.
As many of the variables were distinctively non normally distributed, Cochran-Mantel-Haenszel (CMH) analyses of ranks were performed on each variable in parallel with the MANOV As (Agresti 1990 ). An inspec tion of the means over the four evaluations indicated an almost steady increase or decline in scores, there fore, the CMH test for monotonic correlation was ap plied. We have previously proven that the CMH is a particularly powerful method to analyze repeated mea sures as it places fewer restrictions on the data, and is more sensitive to patterns of change ).
As discussed previously, a critical issue in the con sideration of the effect of antipsychotic medication on negative symptoms is if any of this effect is indepen dent of the effect on positive symptoms, the effect of EPS, and/or the effect on depression. We utilized sev eral methods in an attempt to disentangle these possi ble interrelationships. First, changes between baseline and week three were calculated for each patient on each scale. Spearman correlations between changes in nega tive symptoms and changes in positive symptoms (dis organization dimension and psychoticism dimension), changes in extrapyramidal side effects measured by the SA-EPS, and changes in depression rated on the HAM D (mood) were performed to determine if the negative symptoms were changing independently of these items that are known to engender "secondary" forms of nega tive symptoms. Next, we used a multiple regression model, with the change in ratings of negative symp toms as the dependent measure in a model that in cluded the change in psychotic symptoms, the change in disorganization, the change in EPS, and the change in depressive symptoms.
RESULTS
Fifty-nine patients met the inclusion criteria, provided informed consent, and entered the drug wash. Fifty one (86.4%) completed the three-week wash. Of the eight patients who did not complete the wash, 3 be came threatening or physically aggressive and 5 re quested that the wash be terminated. There were no diff erences in the age, gender, duration of illness, or number of hospitalizations between those who com pleted the wash and those who did not. There were also no signmcant differences in any rating of psy chopathology at baseline, week 1, or a change from baseline to week 1 between those who completed the three week drug-free period and those who did not.
The weekly means and standard deviations of the ratings of psychopathology and side effects appear in Table 1 . Three of the seven ratings showed signibcant changes using both methods of analysis (i.e., MANOVA and CMH). The Simpson-Angus scale for EPS was close to statistical signibcance using the MANOV A, and was signiftcant using the CMH test for monotonic correla Correlations between change scores are shown in Factor Angus (mood)
1.00 -0.08 1.00 0.08 -0.3 1.00 Table 2 . As there was a signmcant worsening in mean ratings of the negative and disorganization symptom dimensions, we were particularly curious if the wor sening in negative symptoms was correlated with the worsening in disorganization symptoms. We were also interested if individual changes in ratings of psychotic symptoms or depression were correlated with in dividual changes in negative symptoms, as these could also be involved in the change in negative symptoms.
The changes in the negative symptom dimension was correlated with changes in both disorganization and psychosis (r2 = 0.14, P = .02; r2 = .18, P = .03). that it is essential to attempt to disentangle "primary"
versus "secondary" negative symptoms, there has been much debate about the best method of doing so.
There are at least two strategies in approaching this problem. One, that has been proposed by Carpenter and colleagues, involves a determination at the level of the rater as to whether negative symptoms are pri mary or secondary. They have developed speciftc criteria and a rating instrument, and using these along with adequate training, have demonstrated good lev els of reliability, and several potential validators (Bucha nan et al. 1989; Buchanan et al. 1990; Carpenter et al. 1985b; Kirkpatrick et al. 1989b ).
However, concerns about the reliability and valid ity of this approach persist. Negative symptoms as a whole are diffi cult to rate. In our center, we have ob served that great care must be taken to maintain ade quate levels of reliability and calibration among raters, 
1992; unpublished data).
The alternate approach involves ratings of negative symptoms based on objective measures, with concom itant assessment of the putative confounding factors (Le., positive symptoms, depression, akinesia) and then determining if changes in negative symptoms are related to changes in these potential causes of second ary negative symptoms. If the changes are interrelated, the assumption is that the change in the negative symp toms is likely due to change in "secondary" negative symptoms, although this does not eliminate the possi bility that they may be changing at similar rates, but independent of each other. Because this method obvi ates the need for potentially unreliable judgments re garding the source of a particular symptom, it is more cumbersome. Using such an approach, we discovered that both the means of the negative symptoms and the disorganization worsened signifIcantly whereas the mean of the psychotic symptoms, depressive symp toms, and EPS did not change during the three weeks following the discontinuation of antipsychotic medica tion. The individual changes in psychosis and disor ganization were positively correlated with the in dividual change in negative symptoms, whereas, the individual changes in depression and EPS were not.
Likewise, the changes in psychosis and the changes in disorganization accurately predicted the change in negative symptoms in a multiple regression analysis, while the change in depression and EPS did not add signiftcantly to this model.
There have been numerous studies examining response to antipsychotic discontinuation with the majority using "relapse" as their primary outcome mea sure (Prien et al. 1972; Andrews et al. 1976; Hogarty et al. 1976; Marder et al. 1979; Brown and Laughren 1981; Weinberger et al. 1981; Zander et al. 1981; Hein ricks and Carpenter 1985; Perenyi et al. 1985; Dencker et al. 1986; Lieberman et al. 1987; Glazer et al. 1989; Kirkpatrick et al. 1989a; van Kammen et al. 1989; Gree n et al. 1990; Davidson et al. 1991; Dixon et al. 1993 ). In vestigators have utilized a variety of criteria for a deftni tion of relapse, that tends to focus on positive symp tomatology, and relatively few have reported mean changes in negative symptomatology. In these various studies, withdrawal of antipsychotic medication was reported to produce a heterogeneous response in psy chopathology with relapse rates ranging from 25% to 60%. Our ftnding of the mean ratings of negative symp toms worsening signiftcantly following antipsychotic discontinuation is in agreement with the ftndings of Breier and co-workers (1987) who reported similar results, but differs from those of Dixon and colleagues (1993) who saw no change in negative symptoms, and from Naber and associates (1985) who discovered that negative symptoms improved after antipsychotics were discontinued. In the present study, antipsychotics were discontinued for 3-weeks compared to 4-weeks in the Breier and Dixon studies and only 12 days in the Naber study. It is possible that negative symptoms may have worsened if the patients in the Naber study had re mained off antipsychotics for a longer period of time.
Other studies have noted variable responses of nega tive symptoms during antipsychotic discontinuation with some individuals showing improvement, some re maining the same, and others worsening (Hogarty et al. 1976; Dencker et al. 1986; Glazer et al. 1989; van Kam men et al. 1989 ). Although we discovered that the mean ratings of negative symptoms worsened signihcantly during the 3-week period, there was variability within the group with negative symptoms improving in 13 pa tients, not changing in 6 patients, and worsening in 32
patients.
In the present study, positive symptoms showed less consistent results with the mean symptom ratings of disorganization worsening, and the mean ratings of psychotic symptoms remaining unchanged. Utilizing the BPRS, Breier et al. (1987) and Naber et al. (1985) reported an exacerbation of positive symptoms, whereas, Dixon et al. (1993) found them not to change.
The differences between our fIndings and the other studies is most likely related to the differences in the rating instruments as well as that they analyzed the data using two-dimensional models rather than the three dimensional model used here; therefore, if we combine psychotic and disorganization symptoms and defIne them as "positive" symptoms, we also demonstrate an overall worsening in the mean ratings of positive sym ptomatology. Even though mean ratings of disorgani zation and psychosis worsened and remained un changed, respectively, there was variability of response among the patients. Eleven patients experienced im provement in disorganization, 5 showed no change, and 35 worsened; 21 patients showed an improvement in ratings of psychosis, 14 did not change, and 16 wor sened. A possible explanation for the smaller increase in psychotic symptoms in the present study is the du ration of the medication free period. The three-week period in the present study is relatively brief compared to the duration used in the other investigations (Prien et al. 1972; Andrews et al. 1976; Hogarty et al. 1976; Brown and Laughren 1981; Perenyi et al. 1985; Dencker et al. 1986; Lieberman et al. 1987; van Kammen et al. 1989; Green et al. 1990; Davidson et al. 1991) and it is likely that we would have seen a greater worsening of psychosis if the drug-free period had been extended. These fIndings confIrm Goldman's conclusion that the HAM-D total score is a nonspecihc measure of a vari ety of types of symptoms (depression, negative symp toms, agitation, and somatic distress) in schizophrenic patients. We agree that more specihc and sensitive as sessment techniques are needed to assess depression in schizophrenic patients.
EPS decreased signihcantly during the period off antipsychotic medication, and regarding negative symptoms, it would be expected that it would reduce them; therefore, it is not surprising that the observed change in EPS was not associated with a change in nega tive symptoms. Other forms of "secondary" negative symptoms that these data do not account for include environmental influences; for example, being in the hospital for three weeks may be considered demoraliz ing and amotivating, and may lead to behavior which is negative. Most investigators agree that demoraliza tion and environmental deprivation may produce sec ondary negative symptoms, however, this is diffIcult to quantify. The supposition that environmental depri vation produces negative symptoms is speculatively based on literature relating chronicity to general effects of social and intellectual isolation. We did not have the ability to measure demoralization and environmental deprivation and were therefore, unable to ascertain if a change in them during the drug-free period may have been portrayed as a worsening of negative symptoms.
In summary, although these data lend some over all support to the idea that typical antipsychotics are efficacious in the treatment of negative symptoms, they do not clearly inform the underlying mechanisms.
Negative symptoms increased signihcantly following discontinuation of antipsychotic medication, and this increase was associated with changes in psychosis and disorganization suggesting that at least a portion of this change was caused by a worsening of "secondary" negative symptoms; however, the changes in the vari ous putative causes of secondary negative symptoms only accounted for 30% of the variance of the change in negative symptoms, inferring that other deter minants, possibly involving a change in "primary" negative symptoms may also be occurring. 
